These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 14574076)

  • 21. Anticoagulation in acute cardiac care in patients with chronic kidney disease.
    Reddan D; Szczech LA; O'Shea S; Califf RM
    Am Heart J; 2003 Apr; 145(4):586-94. PubMed ID: 12679753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulants in acute coronary syndromes.
    Turpie AG
    Am J Cardiol; 1999 Sep; 84(5A):2M-6M. PubMed ID: 10505536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia.
    Nikolsky E; Dangas GD
    Semin Thromb Hemost; 2004 Jun; 30(3):305-14. PubMed ID: 15282653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia.
    O'Shea SI; Ortel TL; Kovalik EC
    Semin Dial; 2003; 16(1):61-7. PubMed ID: 12535303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bivalirudin: a new approach to anticoagulation.
    Nawarskas JJ; Anderson JR
    Heart Dis; 2001; 3(2):131-7. PubMed ID: 11975781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition.
    Reginelli JP; Chew D
    J Interv Cardiol; 2002 Apr; 15(2):141-6. PubMed ID: 12063809
    [No Abstract]   [Full Text] [Related]  

  • 27. Direct thrombin inhibitors (part 2 of 2).
    Arora UK; Dhir M
    J Invasive Cardiol; 2005 Feb; 17(2):85-91. PubMed ID: 15687531
    [No Abstract]   [Full Text] [Related]  

  • 28. Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors.
    Gurm HS; Bhatt DL
    Am Heart J; 2005 Jan; 149(1 Suppl):S43-53. PubMed ID: 15644793
    [No Abstract]   [Full Text] [Related]  

  • 29. Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology.
    Ahrens I; Smith BK; Bode C; Peter K
    Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):609-20. PubMed ID: 17696810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
    Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome.
    Frere C; Laine M; Lemesle G; Morange PE; Paganelli F; Dignat-George F; Resseguier N; Guieu R; Camoin-Jau L; Bonello L
    Platelets; 2019; 30(1):105-111. PubMed ID: 29172822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
    Van Cott EM; Roberts AJ; Dager WE
    Semin Thromb Hemost; 2017 Apr; 43(3):270-276. PubMed ID: 28052306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Lewis BE; Hursting MJ
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):57-68. PubMed ID: 17187457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes.
    Maraganore JM; Adelman BA
    Coron Artery Dis; 1996 Jun; 7(6):438-48. PubMed ID: 8889359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hirudin: clinical potential of a thrombin inhibitor.
    Johnson PH
    Annu Rev Med; 1994; 45():165-77. PubMed ID: 8198374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New developments in parenteral anticoagulation for arterial and venous thromboembolism.
    van Es N; Bleker SM; Büller HR; Coppens M
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):203-13. PubMed ID: 23953908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hirudin (desirudin) and Hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early Reperfusion Occlusion (HERO-2) Study.
    White HD; Ellis CJ; French JK; Aylward P
    Aust N Z J Med; 1998 Aug; 28(4):551-4. PubMed ID: 9777138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions.
    White HD; Chew DP
    Expert Opin Pharmacother; 2002 Jun; 3(6):777-88. PubMed ID: 12036417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
    Gibson CM; Morrow DA; Murphy SA; Palabrica TM; Jennings LK; Stone PH; Lui HH; Bulle T; Lakkis N; Kovach R; Cohen DJ; Fish P; McCabe CH; Braunwald E;
    J Am Coll Cardiol; 2006 Jun; 47(12):2364-73. PubMed ID: 16781360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translational success stories: development of direct thrombin inhibitors.
    Coppens M; Eikelboom JW; Gustafsson D; Weitz JI; Hirsh J
    Circ Res; 2012 Sep; 111(7):920-9. PubMed ID: 22982873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.